Salute e Benessere

Fractus Expands Licensing Program into the Heart of Medical Device Tech

In the field of Medical Device Tech, implantable devices are gaining increasing significance. Nowadays everything is connected. This is the reason why implantable devices require wireless connectivity. In this context, Fractus' antenna technology plays a crucial role by enabling manufacturers to achieve maximum antenna performance within minimal space. Fractus' pioneering antenna technology has revolutionized remote patient monitoring, catalyzing the widespread adoption of...
PR Newswire
22/01/2024

Publication of data from WIL-31 study marks a milestone in improving long-term…

The WIL-31 study (NCT04052698) was a prospective, multinational, open-label, non-controlled phase III study assessing wilate® prophylaxis in preventing bleeds in VWD. Efficacy was assessed in 33 adult and pediatric VWD patients aged 6 years and older from 14 centers in eight countries, with patients receiving wilate®prophylaxis two or three times weekly for 12 months. All patients had taken part in a prospective 6-month run-in study (WIL-29) during which they received on-demand treatment with…
PR Newswire
22/01/2024

SKF Awarded EcoVadis Platinum Rating for fourth year running

Magnus Rosén, Head of Sustainability at SKF, says, "We are proud to have been awarded the EcoVadis Platinum Medal for the fourth year running. This rating reflects not only the ambitious goals we have set for ourselves and the value chain but also how sustainability sits at the heart of SKF, embedded in our purpose, our strategy and in our strive to bring positive impact across the organization worldwide." Magnus Rosén, Head of Sustainability at SKF, says, "We are proud to have…
PR Newswire
22/01/2024

Response Plus Medical announces strategic acquisition of UK-based Prometheus as…

Presently, RPM operates 500 clinics catering to the oil & gas and industrial sectors, boasting a tier-one client roster that includes prominent names such as ADNOC, Schlumberger, Oxy, TOTAL, and Halliburton. Prometheus acquisition will provide opportunity to extend its coverage to Global Oil majors and reputed Defense provider serviced by Prometheus, including Shell, Chevron, ACKER BP, DCAS, the United Kingdom's Military and Royal Flight of Oman, and the UK Security, Defense and NHS…
PR Newswire
22/01/2024

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

"Reaching this milestone illustrates the strong progress being made under our agreement with Curium – a global leader in nuclear medicine and an expert in developing, manufacturing and commercializing world-class radiopharmaceutical products," said Curasight's CEO Ulrich Krasilnikoff. "Today's news is also a testament to the hard work and commitment of our team in pursuing our mission to use Curasight's uPAR theranostic platform to improve cancer treatment with more accurate…
PR Newswire
22/01/2024

Sandoz announces agreement to acquire CIMERLI® business from Coherus…

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASECIMERLI ® *, a ranibizumab biosimilar, is interchangeable with LUCENTIS ® ** (ranibizumab-injection) for all approved indicationsAcquisition strengthens Sandoz ophthalmology portfolioBasel, January 22, 2024– Sandoz, the global leader in generic and biosimilar medicines, has signed an agreement to acquire the US biosimilar ranibizumab CIMERLI ® * (ranibizumab-eqrn) from Coherus BioSciences, Inc...
Nasdaq GlobeNewswire
22/01/2024

3D Bioprinting in Medical Market to Reach $4.9 Billion, Globally, by 2032 at…

Request Sample of the Report on 3D Bioprinting in Medical Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/172037 Request Sample of the Report on 3D Bioprinting in Medical Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/172037 Prime determinants of growth Rise in prevalence of chronic diseases, surge in usage of 3D bioprinting in biomedical applications, and advancements in 3D bioprinting drive the growth of the global 3D...
PR Newswire
22/01/2024

Kindred confirms public cash offer from FDJ

Following press articles regarding the strategic review process, including specific information on a potential public offer by FDJ, Kindred confirms that FDJ has offered to acquire the entire outstanding share capital of Kindred. The takeover offer from FDJ is expected to be announced on Monday morning (22 January 2024), before opening of the market. Following press articles regarding the strategic review process, including specific information on a potential public offer by FDJ, Kindred...
PR Newswire
22/01/2024

xTool's First-Ever Brand Safety Campaign Kicks Off with a Notable Trade-In…

Beginning in 2024, xTool will annually launch a safety-focused campaign each January. The campaign will openly share xTool's safety protocols in product development and brand services, actively seek user feedback, and provide direct, honest responses. Beginning in 2024, xTool will annually launch a safety-focused campaign each January. The campaign will openly share xTool's safety protocols in product development and brand services, actively seek user feedback, and provide direct, honest...
PR Newswire
22/01/2024

Antibody Therapeutics Market Size to Grow USD 364180 Million by 2029 at a CAGR…

Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-6L16385/Global_Antibody_Based_Therapeutics_Market Claim Your Free Sample Now:https://reports.valuates.com/request/sample/QYRE-Auto-6L16385/Global_Antibody_Based_Therapeutics_Market Major Factors Driving the Growth of Antibody Based Therapeutics Market A number of reasons, including developments in biotechnology, notably in the area of monoclonal antibody technology, which has improved the...
PR Newswire
21/01/2024

Postoperative Acute Pain Market to Grow Immensely at a CAGR of 7.9% During the…

Key Takeaways from the Postoperative Acute Pain Market Report Key Takeaways from the Postoperative Acute Pain Market Report Discover which therapies are expected to grab the major postoperative acute pain market share @Postoperative Acute Pain Market Report Postoperative Acute Pain Overview Acute postoperative pain is a normal response to surgical intervention. It not only contributes to delayed recovery and extended hospital stay but also elevates the risk of complications...
PR Newswire
19/01/2024

Liquid Biopsy in Cancer Diagnostics Global Market is Likely to Increase at a…

Key Takeaways from the Liquid Biopsy in Cancer Diagnostics Market Report Key Takeaways from the Liquid Biopsy in Cancer Diagnostics Market Report To read more about the latest highlights related to liquid biopsy in cancer diagnostics market, get a snapshot of the key highlights entailed in theGlobal Liquid Biopsy in Cancer Diagnostics Market Report Liquid Biopsy in Cancer Diagnostics Overview Liquid biopsy is a revolutionary approach in cancer diagnostics that has emerged as...
PR Newswire
19/01/2024

Information on the Total Number of Voting Rights (Denominator) following…

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 10 convertible bonds in Oxurion resulting in a EUR 250,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion.Leuven, BELGIUM – January 19, 2024 – 07.00 PM CET– In accordance...
Nasdaq GlobeNewswire
19/01/2024

ONWARD® to Participate in Degroof Petercam Healthcare Conference

CEO Dave Marver will provide update on the Company's progress toward launch of its first therapy later this year On Wednesday, January 24, 2024, CEO Dave Marver will update conference attendees on the Company's progress toward commercializing ARC-EX ®Therapy, with launch expected later this year. He will also participate in 1:1 and group meetings with investors.*All ONWARD devices and therapies, including but not limited to ARC-IM ®, ARC-EX, and ARC Therapy ™, alone or in...
Nasdaq GlobeNewswire
19/01/2024

Alvotech Provides Update on Status of Biologics License Applications for AVT02…

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the reinspection of Alvotech's facility in Iceland by the U.S. Food and Drug Administration (FDA) which started on January 10, 2024, has been concluded. Following the FDA inspection, Alvotech received a form 483 with one observation. Alvotech expects to provide the FDA with a response in the following days.“We believe that the...
Nasdaq GlobeNewswire
19/01/2024

Zealand Pharma major shareholder announcement: J O Hambro Capital Management

Company announcement – No. 5 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 19 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 18 January 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from J O Hambro Capital...
Nasdaq GlobeNewswire
19/01/2024

Change of management at NTG Nordic Transport Group A/S

Company announcement no. 1 – 2419 January 2024 Change of management at NTG Nordic Transport Group A/S The board of directors accommodates the wish of Group CEO, Michael Larsen, to transition into a more operational role within the Road & Logistics division at NTG Nordic Transport Group (NTG). Jesper E. Petersen will remain CEO of the Road & Logistics division and Michael Larsen will take part of the leadership of the division with specific focus on the Nordic and Baltic...
Nasdaq GlobeNewswire
19/01/2024

FDA grants global Medical Device company Biomimetic Innovations 'Breakthrough…

Biomimetic Innovations Ltdtoday announced that OsStic ®has been granted 'Breakthrough Device' designation by the FDA. The proposed indication statement for this novel new technology is: "OsStic ®Synthetic Injectable Bone Void Filler is a structural, mechanically enhanced bioadhesive for reduction, provisional fixation, or void filling of peri-articular fractures or defects to enhance structural stability where standard fixation alone cannot provide sufficient support for functional...
Nasdaq GlobeNewswire
19/01/2024

Therapeutic Hypothermia Systems Market Worth $396 Million | MarketsandMarkets™.

Browse in-depth TOC on "Therapeutic Hypothermia Systems Market" Browse in-depth TOC on "Therapeutic Hypothermia Systems Market" 132 - Tables 39 - Figures 173 - Pages Therapeutic Hypothermia Systems Market Scope: The cooling devices segment is expected to account for the largest share in 2022. The therapeutic hypothermia systems market, by product, has been segmented into cooling devices, cooling catheters, and cool caps. In 2022, the cooling devices segment...
PR Newswire
19/01/2024

Novartis Lutathera® significantly reduced risk of disease progression or death…

In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) 1 NETTER-2 is the first and only positive Phase III trial for a radioligand therapy (RLT) in the first-line setting, demonstrating the potential of RLTs in earlier linesNovartis, a leader in radioligand therapy,...
Nasdaq GlobeNewswire
19/01/2024

Endo Announces New Data for Dupuytren's Contracture Presented at the American…

The two new Endo-supported research presentations are below: The two new Endo-supported research presentations are below: About Dupuytren's ContractureDC is a lifelong condition that may get worse over time. It's caused by a buildup of collagen in the hand, which forms a rope-like cord that pulls fingers toward the palm so they can't be straightened. As DC progresses, it may become difficult for individuals to use their hand(s) for daily tasks and activities. WHAT IS XIAFLEX ® ? ...
PR Newswire
19/01/2024

Viatris recognised as a Top Employer 2024 in the UK for the second consecutive…

Matthew Salzmann, Viatris Country Manager for the UK, stated, "At Viatris, we work tirelessly across our organzaiton to provide access to medicines, develop solutions, and improve patient health. Not only are we a global healthcare company with a mission to empower people worldwide to live healthier at every stage of life, but we have also created an exceptional workplace for our employees." Matthew Salzmann, Viatris Country Manager for the UK, stated, "At Viatris, we work…
PR Newswire
19/01/2024

Reminder: Welcome to SciBase Capital Markets Day 2024

During SciBase's Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will provide insights into SciBase's future trajectory, and unveil an updated strategic outlook, and long-term strategic goals. The presentations will underscore the company's focus on the USA and shed light on SciBase's ongoing expansion into promising new markets. During SciBase's Capital Markets Day,Pia Renaudin, who assumed the role of CEO inOctober 2023, will provide insights into...
PR Newswire
19/01/2024

Lindab acquires Airmaster and establishes a new product area for decentralised…

Decentralised ventilation is an energy-efficient way to ventilate buildings, especially suitable for renovation projects. By installing fresh air ventilation in each room, there is no need for ventilation ducts or a central system. The technology is particularly suitable in properties where ducting can be difficult, such as in older buildings, or where only part of the building is being renovated. Airmaster's new AMX product is also equipped with an integrated heat pump that enables both cooling…
PR Newswire
19/01/2024
Altri  Comunicati